Zubsolv defended its tablets market share (rolling 4 weeks average) in June, which was unchanged compared to May, and reached 5.4%. In the last week of June (ending 30 of June) Zubsolv prescription recorded a market share of 5.27% and this was also more or less at the same level as last month. Our prescription data indicates more than 1.3 million Zubsolv tablets were prescribed in June. The overall market for buprenorphine/naloxone based opioid addiction treatments continued to show healthy underlying growth in June, with a y/y growth rate of 11.2% (TRx) and 10.3% (quantity), on a monthly basis, at the end of June.